Collegium Pharmaceutical, Inc. COLL Cash Flow

Collegium pharmaceutical, inc. (COLL)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities
Net income (loss)
-12,572	-22,722	-11,435	-21,828	-30,176	-39,128	-65,617	-62,378	-70,439	-74,865	-85,021	-98,203	-101,601	-94,176	-76,142	-59,058	-39,214	-27,255	-21,199	-18,394	-17,838	-17,917	0	0	0
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Amortization expense
21,359	14,752	26,558	55,277	83,996	109,834	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense
745	731	877	851	776	1,074	0	0	0	-	-	-	-	655	401	166	168	171	0	0	0	-	-	-	-
Depreciation expense
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	0	0	0
Lease incentive obligation
-	-	-	-	-	-	-	-	-	34	35	34	35	34	34	35	34	34	34	33	34	34	0	0	0
Stock-based compensation expense
17,216	16,528	16,160	15,949	15,313	13,778	12,258	10,432	8,852	7,945	7,517	7,058	6,507	5,787	5,129	3,991	3,197	2,209	1,223	725	130	22	0	0	0
Non-cash lease expense
217	313	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense for Nucynta asset acquisition
0	-	-	-	-	19,281	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	7	0	0	0
Changes in operating assets and liabilities:
Accounts receivable
288	-4,993	18,101	13,153	19,357	68,231	60,710	63,503	62,687	7,840	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
7,616	1,826	-469	1,409	839	-219	1,605	801	184	497	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
1,029	-2,037	-625	-951	-433	166	-499	582	1,432	1,057	842	1,655	1,436	923	435	318	-1,023	659	16	527	1,154	-183	0	0	0
Refundable PDUFA fee
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,335	0	0	0	-	-	-	-
Accounts payable
-7,594	-5,903	301	-7,752	4,396	6,465	6,697	13,080	2,543	-3,422	-3,956	-462	605	5,569	5,737	3,803	3,977	1,298	389	10	1,018	990	0	0	0
Accrued expenses
-1,649	6,056	586	1,793	1,832	18,995	339	12,316	10,894	-527	12,476	4,336	4,064	6,570	3,956	3,865	-525	362	-760	-63	1,807	943	0	0	0
Accrued rebates, returns and discounts
19,558	12,766	35,063	50,728	60,183	106,593	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease assets and liabilities
-	734	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-4,944	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
-	-676	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
29,683	27,783	54,415	90,180	131,158	169,390	113,806	59,405	-13,667	-67,018	-77,009	-83,856	-87,225	-75,053	-60,705	-47,827	-31,402	-21,567	-20,195	-18,067	-15,857	-17,947	0	0	0
Investing activities
Purchase of intangible asset
0	-	-	-	-	18,877	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
3,951	6,438	7,322	8,688	8,444	5,477	3,876	1,499	1,317	990	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-370,762	-6,438	-7,322	-8,688	-8,560	-24,354	-22,753	-20,376	-20,078	-990	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Financing activities
Proceeds from issuances of common stock from employee stock purchase plans
730	817	817	1,051	1,051	1,117	1,117	978	978	1,141	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of lease note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	59	60	60	61	62	0	0	0
Repayment of term note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Proceeds from the exercise of stock options
6,287	2,046	699	649	2,095	4,255	4,395	4,226	3,015	736	757	772	495	443	159	132	99	517	535	542	531	72	0	0	0
Payments made for employee restricted stock tax withholdings
1,692	822	811	727	832	560	470	373	233	68	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of term note, net of issuance costs of $2,200
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from convertible senior notes, net of issuance costs of $4,956
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for common stock offerings costs
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuances of common stock from public offerings, net of issuance costs of $-, $30 and $1,198, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	137,340	0	0	0	-	-	-	-	-	-	-	-
Proceeds from term loan amendment, net of repayment of amended term loan
-	-	-	-	-	10,021	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of term loan
0	-	-	-	-	-	-	-	-	2,667	2,667	2,667	2,666	2,667	0	0	0	-	-	-	-	-	-	-	-
Proceeds from term loan amendment, net of repayment of amended term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Repayment of asset acquisition obligations
-	-	-	-	-	132,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
324,992	2,041	-33,045	-66,526	-116,640	-117,197	-58,971	-16,588	33,042	33,480	94,751	85,248	85,059	135,558	49,096	49,025	121,505	115,992	121,660	127,918	56,043	12,038	0	0	0
Net decrease in cash, cash equivalents and restricted cash
-16,087	23,386	14,048	14,966	5,958	27,839	32,082	22,441	-703	-34,528	16,583	462	-5,172	57,528	0	0	89,741	-	101,282	109,820	40,178	-5,917	0	0	0
Supplemental disclosure of cash flow information
Cash paid for offering costs
-	-	-	-	-	30	0	0	0	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Cash paid for interest
3,987	709	716	702	651	582	427	293	199	139	179	213	250	284	319	310	335	353	395	337	262	181	0	0	0
Supplemental disclosure of non-cash activities
Offering costs in accrued expenses
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	0	-	-	0	0	-	-	-	-
Acquisition of property and equipment in accounts payable and accrued expenses
-284	134	2,357	2,589	3,942	3,261	1,575	1,096	246	216	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Asset acquisition transaction costs in accounts payable and accrued expenses
0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued royalties discharged upon closing of asset acquisition
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory used in the construction and installation of property and equipment
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Term notes issuance costs in accounts payable and accrued expenses
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Convertible senior notes issuance costs in accounts payable and accrued expenses
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Offering costs in accrued expenses
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivable from stock option exercises in other current assets
-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease assets assumed
-	9,957	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities assumed
-	10,691	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities assumed from Nucynta asset acquisition included in accrued rebates, returns and discounts
-	-	-	-	-	22,406	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accruals of dividends and accretion to redemption value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24,572	0	0	0	-	-	-	-
Conversion of bridge note to preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Accruals of dividends and accretion to redemption value of preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Repayment of term note with proceeds of notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	944	0	0	0